Drugs / Novavax COVID-19 vaccine
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03305341 | May 2025 → Nov 2026 expected | COVID-19 | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06291857 | Dec 2024 → Dec 2025 | COVID-19 | Novavax | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06633835 Comparator | Sep → Dec 2024 | COVID-19 | Novavax | Completed | No outcome recorded |
| Phase 4 | NCT06065176 Comparator | Nov 2023 → Sep 2024 | COVID-19, respiratory tract infectious disorder, upper respiratory tract disorder | Sarang K. Yoon, DO, MOH | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Novavax COVID-19 vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06065176 ↗ |
| Modality | Vaccine | “NOVAVAX COVID-19 VACCINE” NCT03305341 ↗ |
| Route | Intramuscular | “in the deltoid muscle of the arm” NCT06065176 ↗ |